Scientists have identified a new sub-variant of Omicron, officially named NB.1.8.1, and colloquially called Nimbus. First detected in January 2025, it spread rapidly across continents—Asia, the Americas, Europe—making up about 10–11% of global sequenced cases by mid-May The World Health Organization (WHO) classifies Nimbus as a “Variant Under Monitoring (VUM)” as of May 23
Nimbus carries multiple mutations in its spike protein and other critical regions—through a process called recombination, where Omicron lineages mix genetic material. It has about 7 new mutations in spike and 20+ elsewhere, significantly boosting its cell-binding strength and infectivity in lab tests
What’s grabbing attention is the “razor blade throat”—a severe, glass-like sore throat, often accompanied by hoarseness and gastrointestinal issues like nausea, diarrhea, and bloating Otherwise, Nimbus presents familiar COVID symptoms: fever, congestion, fatigue, cough, body aches, and occasional loss of taste or smell .
Current data show no increase in severity—hospitalizations and deaths stay low WHO and CDC deem global risk low, but caution that its high transmissibility could impact vulnerable groups
Fortunately, existing 2024–25 COVID vaccines, including updated boosters, continue protecting against severe disease . Likewise, antiviral treatments like Paxlovid remain effective .
Nimbus is significant for exam aspirants aiming for government posts (teachers, police, banks, railways, defense, civil services like PCS to IAS):
Q1. What is the full scientific name of the new COVID variant known as Nimbus?
Ans: NB.1.8.1.
Q2. Why is the variant called Nimbus?
Ans: Nimbus is a nickname given to NB.1.8.1 for easier public communication, similar to previous nicknames like Kraken or Pirola.
Q3. What makes Nimbus different from earlier variants?
Ans: Nimbus has undergone recombination, meaning it has combined genetic material from different Omicron sub-variants, leading to increased transmissibility and unusual symptoms like razor blade throat.
Q4. Are current vaccines effective against Nimbus?
Ans: Yes, updated COVID-19 vaccines for 2024–25 are still effective in preventing severe illness caused by Nimbus.
Q5. What is the global status of the Nimbus variant according to the WHO?
Ans: As of May 23, 2025, WHO has classified Nimbus as a “Variant Under Monitoring” (VUM).
Q6. Does Nimbus cause more severe disease than previous variants?
Ans: No, current data shows that it does not increase the severity of illness, though it spreads faster.
Q7. What are the primary symptoms of the Nimbus variant?
Ans: Razor blade throat, hoarseness, fever, fatigue, body aches, nausea, diarrhea, and occasional loss of taste or smell.
Q8. What is meant by a Variant Under Monitoring (VUM)?
Ans: It is a classification used by WHO for variants that show potential changes in transmissibility or severity and are under close observation.
Exercise MILAN 2026 India, inaugurated by Defence Minister Rajnath Singh in Visakhapatnam, strengthens maritime cooperation,…
Andhra Pradesh lithium battery gigafactory investment of ₹8,175 crore by Waaree Energies will strengthen India’s…
India joins over 100 nations in condemning Israel’s West Bank actions, reinforcing support for the…
Edge AI Package launched by the U.S. Department of State with $200 million for the…
Reliance ₹10 trillion AI investment aims to build India’s sovereign compute power, making AI accessible…
Japan PM Sanae Takaichi reappointed after historic landslide victory 2026 – detailed analysis for UPSC,…